Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) Net Margin (2016 - 2025)

Historic Net Margin for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to 29.29%.

  • Ascendis Pharma A's Net Margin fell 2008100.0% to 29.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.43%, marking a year-over-year decrease of 709200.0%. This contributed to the annual value of 93.17% for FY2024, which is 667700.0% up from last year.
  • Per Ascendis Pharma A's latest filing, its Net Margin stood at 29.29% for Q3 2025, which was down 2008100.0% from 25.47% recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Net Margin peaked at 13148.14% during Q2 2021, and registered a low of 8417.16% during Q1 2021.
  • Over the past 5 years, Ascendis Pharma A's median Net Margin value was 29.29% (recorded in 2025), while the average stood at 259.08%.
  • The largest annual percentage gain for Ascendis Pharma A's Net Margin in the last 5 years was 65791700bps (2022), contrasted with its biggest fall of -118157400bps (2022).
  • Quarter analysis of 5 years shows Ascendis Pharma A's Net Margin stood at 123.14% in 2021, then crashed by -636bps to 905.96% in 2022, then soared by 97bps to 29.19% in 2023, then surged by 57bps to 12.41% in 2024, then tumbled by -136bps to 29.29% in 2025.
  • Its Net Margin was 29.29% in Q3 2025, compared to 25.47% in Q2 2025 and 93.81% in Q1 2025.